Edwards Lifesciences price target raised to $90 from $88 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $88 and keeps an Overweight rating on the shares post the Q4 report. The company reported “solid” 9% organic growth and upside to margins, which drove the earnings beat, the analyst tells investors in a research note. The firm expects the stock to continue to move higher driven by increased confidence in Edwards’ intermediate and long-term growth goals, product launches, and clinical catalysts.